Yukako Ogi

Yukako Ogi

Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan

Direct Impact

Concepts for which Yukako Ogi has direct influence:

spiriva respimat
persistent asthma
intravenous solution
mild moderate
safety effectiveness

External impact

Concepts related to the work of other authors for which Yukako Ogi has influence:

early removal
pericardial drains
analgesic requirements
tamponade complicating catheter ablation
opiate analgesia
pulmonary vein isolation
afca procedures

Prominent publications by Yukako Ogi

KOL-Index: 41 INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serious bleeding (Group A) or required an urgent procedure (Group B). METHODS: The primary endpoint ...
Known for
Interim Japanese | Idarucizumab Bleeding | All-Case Post-Marketing Surveillance | Activated Thromboplastin Time
KOL-Index: 2 The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.Main objectivesTo investigate the safety and effectiveness of Spiriva Respimat in patients with asthma under the real-world use.Primary outcomesThe primary Outcome is the absolute and relative ...
Known for
Absolute Frequency | Asthma Status
KOL-Index: 2 Study to evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical conditionMain objectivesStudy to to evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical conditionPrimary outcomesAny suspected ADRs (primary outcome), Serious AEs, and AEs for important potential risks(hypersensitivity, thrombotic ...
Known for
Coagulation Test
KOL-Index: 2 The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use Detailed Description The study is Post-Marketing Surveillance on the Long-Term Use of Spiriva Respimat in Japanese patients with mild to moderate persistent asthma. The patient population who receive Spiriva Respimat and the safety ...
Known for
Safety Effectiveness | Respimat Asthmatics | Objective Investigate | Surveillance Spiriva
KOL-Index: 2 The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with mild to moderate persistent asthma under the real-world use was not confirmed in clinical trials.Main objectivesTo investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under the real-world use.Primary outcomesThe primary ...
Known for
Absolute Frequency | Asthma Status

Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172